Osteoporosis: latest news - GoINPHARMA
Saturday, 15 December 2018 - 5:40


MSD discontinues osteoporosis drug development

MSD has stated it will interrupt the development of odanacatib, its new experimental osteoporosis drug. An independent analysis of major cardiovascular events has confirmed, indeed, an increased risk of stroke. The study was conducted in postmenopausal women. The company will…